fosmetpantotenate
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2017 (NCT03041116)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Pantothenate kinase 1AGONIST
PANK1 agonist
- Unspecified targetOTHER
Phosphopantothenate replacement therapy
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)CCNC(=O)[C@H](O)C(C)(C)CO[P@](=O)(N[C@@H](C)C(=O)OC)OC1=CC=CC=C1- Mol. weight
- 474.4419 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSFD7K3338YY ↗
- ChEMBLCHEMBL6067991 ↗
- ChEMBLCHEMBL3989938 ↗
Also known as
- fosmetpantotenate
- fosmetpantotenate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03041116 | Phase 3 | Jun 1, 2017 | Travere |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Travere | For profit | 1 | 1 | 1 | 2017 |
1 organizations
Page 1 / 1